Travere Therapeutics (TVTX) Return on Sales (2014 - 2026)

Travere Therapeutics has reported Return on Sales for 13 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.03%, up 3.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.06% in Q3 2023, with the low at 0.0% in Q4 2025.
• Historically, Return on Sales has averaged 0.01% across 5 years, with a median of 0.0% in 2025.
• Annual changes were most pronounced in 2023 — Return on Sales rose 6 bps — and 2024, when it declined 6 bps.
• Travere Therapeutics' Return on Sales stood at 0.01% in 2022, then plunged by 105 bps to 0.0% in 2023, then surged by 100 bps to 0.0% in 2024, then slumped by 131473 bps to 0.0% in 2025, then soared by 94 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.